Condition
Drug Metabolism, Poor, CYP2D6-Related
Total Trials
7
Recruiting
2
Active
2
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
14.3%
1 terminated out of 7 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results75% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Recruiting2
Not Yet Recruiting1
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (7)
Showing 7 of 7 trials
NCT06322238Phase 2Recruiting
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
NCT06837571Not Yet Recruiting
Methadone Dose Monitoring With a Remote Medication Monitor
NCT05981573Recruiting
Assessment of Methadone Dose Taken
NCT02378220Not ApplicableCompleted
Pharmacogenetic Testing Among Home Health Patients
NCT02191358Completed
YouScript IMPACT Registry
NCT02428660Not ApplicableCompleted
Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM
NCT01289938Phase 1TerminatedPrimary
Pharmacogenetic Factors and Side Effects of Metoclopramide and Diphenhydramine
Showing all 7 trials